CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Drugs (New Approvals & NDA)
Original article

Over-The-Counter Monograph Drug User Fee Program (OMUFA)

RegulatoryNeutral
AI Analysis

Summary

The FDA is considering an Over-The-Counter Monograph Drug User Fee Program (OMUFA) as a potential funding mechanism to supplement congressional appropriations for nonprescription monograph drugs.

Importance:2/10
Sentiment:
0.00
OTCmonographuser feeregulatoryFDA

Read the original article

Published by FDA Drugs (New Approvals & NDA) on July 29, 2026 12:58 PM

Read Original